US regulators approved GSK's blood cancer drug, a decision that will allow the company to bring the medicine back to the world’s biggest pharmaceutical market after questions about its effectiveness led to its withdrawal in 2022 https://t.co/X4muiEKfcL ...

Regulatory Approval - GSK's blood cancer drug approval is in doubt after failing to secure backing from a US regulatory panel [1] Pharmaceutical Industry - The outcome potentially impacts GSK's market position in the blood cancer drug sector [1]